ALK-Abello has introduced Jext, a new adrenaline auto-injector (AAI) to use in an emergency to counter an allergic reaction (anaphylaxis) caused due to insect stings or bites, foods, drugs and other allergens, as well as idiopathic or exercise induced anaphylaxis.

AAI is available in 300 and 150 microgram doses and has a maximum shelf-life of 24 months from date of manufacture representing a potential cost saving of 18.4% compared to currently available AAI’s with 18 months shelf-life.

AAI features a locking needle shield which offers needle protection automatically after use, thus reducing the risk of a needle stick injury.

Jext does not require any special storage conditions other than not to freeze, providing patients with confidence in carrying their device with them in any climatic conditions, particularly during summer months.

Anaphylaxis Campaign CEO Lynne Regent said they feel strong that adrenaline injectors should be made available to all those affected by anaphylaxis and their organisation offers support and guidance to patients who have been prescribed with these devices.

Allergy UK executive director Lindsey McManus said the new features in Jext will give considerable reassurance and confidence to those that need to use an adrenaline auto-injector, whether they are allergic themselves or if they are a carer of someone with severe allergy.